The overarching mission of the Experimental Therapeutics (ET) Program is to discover and validate therapeutic targets and subsequently identify, develop, and test novel therapeutic strategies and biomarkers. The close collaboration between discovery scientists and clinicians allows a multifaceted assessment of therapeutic strategies in iterative cycles from bench to bedside. Discoveries within the rich scientific environment of the HDFCCC have resulted in the development of a large number of biotech start-ups, and the movement of discoveries into the private sector for clinical implementation. Most often, this takes the form of early biotech start-ups launched by UCSF faculty. Thus, this discovery cycle can also include `bench to boardroom,' since the lengthy arc from initial discovery to clinical approval and adoption requires industrial participation ranging from early biotech start-ups to pharmaceutical companies. Genomic and molecular imaging target validation are a central clinical focus of the ET Program. Promising clinical translational strategies are tested in the HDFCCC Early Phase Clinical Trials Unit. In addition to facilitating translation of science from its members, the ET Program serves as a clinical translational hub for the entire HDFCCC, since all clinical investigators in the ET Program participate in disease-specific Site Committees. These investigators consequently serve as a two-way conduit of collaborative interactions between the Site Committees and the ET Program. Research in the ET Program is conducted under two cross-cutting themes: Theme 1: Targeting Signal Transduction in Cancer Theme 2: Targeting Epigenetic Modulation, Cellular Homeostasis, and the Tumor Environment ET Program: Key Metrics Membership (13 departments, 2 schools) 43 Full 31 Associate 12 Cancer-relevant Funding (direct costs as of $21,511,484 05/31/2017) NCI $3,071,012 14% Peer-reviewed $3,740,309 17% Non-peer-reviewed $14,700,162 68% Cancer-relevant Publications (1/2012-7/2017) 672 Inter-programmatic 262 39% Intra-Programmatic 150 22% High-Impact 189 28% Accruals to Clinical Trials (2016) 237 63 Therapeutic 133 59 Other Interventional 0 2 Non-interventional 104 2
Sannino, Sara; Guerriero, Christopher J; Sabnis, Amit J et al. (2018) Compensatory increases of select proteostasis networks after Hsp70 inhibition in cancer cells. J Cell Sci 131: |
Lam, Christine; Ferguson, Ian D; Mariano, Margarette C et al. (2018) Repurposing tofacitinib as an anti-myeloma therapeutic to reverse growth-promoting effects of the bone marrow microenvironment. Haematologica 103:1218-1228 |
Truillet, Charles; Parker, Matthew F L; Huynh, Loc T et al. (2018) Measuring glucocorticoid receptor expression in vivo with PET. Oncotarget 9:20399-20408 |
Phillips, Kathryn A; Trosman, Julia R; Deverka, Patricia A et al. (2018) Insurance coverage for genomic tests. Science 360:278-279 |
Phillips, Kathryn A (2018) Evolving Payer Coverage Policies on Genomic Sequencing Tests: Beginning of the End or End of the Beginning? JAMA 319:2379-2380 |
Puri, Sapna; Roy, Nilotpal; Russ, Holger A et al. (2018) Replication confers ? cell immaturity. Nat Commun 9:485 |
An, Zhenyi; Aksoy, Ozlem; Zheng, Tina et al. (2018) Epidermal growth factor receptor and EGFRvIII in glioblastoma: signaling pathways and targeted therapies. Oncogene 37:1561-1575 |
Behr, Spencer C; Villanueva-Meyer, Javier E; Li, Yan et al. (2018) Targeting iron metabolism in high-grade glioma with 68Ga-citrate PET/MR. JCI Insight 3: |
Rubenstein, James L; Geng, Huimin; Fraser, Eleanor J et al. (2018) Phase 1 investigation of lenalidomide/rituximab plus outcomes of lenalidomide maintenance in relapsed CNS lymphoma. Blood Adv 2:1595-1607 |
An, Zhenyi; Knobbe-Thomsen, Christiane B; Wan, Xiaohua et al. (2018) EGFR Cooperates with EGFRvIII to Recruit Macrophages in Glioblastoma. Cancer Res 78:6785-6794 |
Showing the most recent 10 out of 192 publications